(Q34168363)

31 July 2017

1 reference

title

Introduction to current and future protein therapeutics: a protein engineering perspective (English)

1 reference

31 July 2017

Paul J Carter

1

1 reference

PubMed ID

21371474

31 July 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Experimental Cell Research

31 July 2017

1 reference

31 July 2017

317

1 reference

31 July 2017

9

1 reference

31 July 2017

1261-1269

1 reference

Biopharmaceutical benchmarks 2010

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Protein therapeutics: a summary and pharmacological classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Advances in targeted therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Metrics for antibody therapeutics development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Antibodies to watch in 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Therapeutic antibodies for autoimmunity and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Expression in Escherichia coli of chemically synthesized genes for human insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Insulin and its analogs: actions via insulin and IGF receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Enhancement of therapeutic protein in vivo activities through glycoengineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Fc-based cytokines : prospects for engineering superior therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Strategies to extend plasma half-lives of recombinant antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Designing CD4 immunoadhesins for AIDS therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

PEGylation of therapeutic proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

The impact of PEGylation on biological therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Therapeutic antibody fragments with prolonged in vivo half-lives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Thrombocytopenia caused by the development of antibodies to thrombopoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Fully human antibodies from transgenic mouse and phage display platforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Human monoclonal antibodies from transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Phage display derived therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Escherichia coli secretion of an active chimeric antibody fragment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Assembly of a functional immunoglobulin Fv fragment in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

High level Escherichia coli expression and production of a bivalent humanized antibody fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Strategies and challenges for the next generation of therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Therapeutic antibodies: successes, limitations and hopes for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Monoclonal antibodies as innovative therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Targeting antibodies to the cytoplasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

The blood-brain barrier in health and chronic neurodegenerative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Monoclonal antibodies: versatile platforms for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Network systems biology for drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Network medicine: a network-based approach to human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Potent antibody therapeutics by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Quantitative Estimation of the Hybridization of Rabbit Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Catumaxomab: clinical development and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Recombinant approaches to IgG-like bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Antibody-drug conjugates: targeted drug delivery for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Antibody-drug conjugates for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Increasing the serum persistence of an IgG fragment by random mutagenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Molecular engineering and design of therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Enhanced antibody half-life improves in vivo activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Engineered therapeutic antibodies with improved effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

From the bench to the bedside: ways to improve rituximab efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Engineering novel binding proteins from nonimmunoglobulin domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Engineered protein scaffolds as next-generation antibody therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Display scaffolds: protein engineering for novel therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.02.013

10.1016/J.YEXCR.2011.02.013

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

21371474